The molecular characterization of cytogenetic abnormalities has not only provided insights into the mechanisms of leukemogenesis but also led to the establishment of new treatment strategies targeting these abnormalities and thereby further improve the prognosis of patients. We analyzed the prognosis of 1091 Chinese patients with newly diagnosed acute lymphoblastic leukemia (ALL) and explored the prognostic impacts of a large number of cytogenetic/molecular abnormalities. It was demonstrated that, in both B-and T-ALL settings, the prognosis was negatively correlated to the age as reported to date. For childhood T-ALL patients, it was also documented that the HOX11 expression represented a favorable prognostic factor as it was in adult ones. We identified CRLF2 overexpression as an intermediate-risk marker and Ik6 variant of IKZF1 gene as a high-risk one when stratifying pediatric B-ALL cases according to cytogenetic/molecular risks. We also found that Ik6 variant and CRLF2 overexpression had an important role in dictating the prognosis of Ph-negative patients, which may be useful markers in guiding the treatment of ALL in the future, with tyrosine kinase inhibitors on the other hand reversing the fate of Ph-positive ALL patients.
INTRODUCTION
To date, a growing number of genetic aberrations have been used as predictive markers of prognosis in acute lymphoblastic leukemia (ALL). 1, 2 Interestingly, the characterization of molecular and cytogenetic abnormalities has not only provided insights into the mechanisms of leukemogenesis but also led to the establishment of new treatment strategies targeting these abnormalities, which has improved the prognosis of patients in a continuous way. For example, the t(1;19)(q23;p13)/TCF3-PBX1, which had once been considered as predicting poor outcome in childhood B-ALL, has become a good prognostic factor with a 5-year disease-free survival up to 90%, since the traditional antimetabolite-based regimen was updated to intensified chemotherapy. 3 Likewise, Ph/BCR-ABL in newly diagnosed ALL patients was known as a high-risk prognostic factor, but the emergence of tyrosine kinase inhibitors (such as Imatinib, Dasatinib, etc.) in recent years has made significant improvement of complete remission (CR) rates, providing patients with a good recipient status for allografts. 4, 5 It is believed that the prognosis of Ph/BCR-ABL would be re-evaluated after follow-up of patients for several years.
The recognition of clinical value of molecular markers in ALL made people try to stratify different risk groups based on their prognostic significance, so as to offer guidance for appropriate treatment. After the efforts of nearly two decades, hematology/ oncology community possesses reliable cytogenetic and/or molecular risk groups for childhood B-ALL. 6 However, we know of few prognostic markers for adult B-ALL aside from Ph and MLL-related abnormalities, and a similar situation exists on adult T-ALL. As a result, it is always a topic of interest to find more markers to optimize the classification of childhood B-ALL, and more importantly, an even urgent challenge is to discover new important markers for adult B-ALL or T-ALL. The good news is, with the deepening of studies on pathogenesis of ALL and the introduction of new technologies, novel molecular markers of prognostic relevance continue to be discovered. For example, recently, the variant transcripts of IKZF1 gene and overexpression of CRLF2 gene were reported to exert prognostic impact in B-ALL. 7 --13 However, the prognostic significances of these new molecular markers should be further confirmed in large samples in the background of new treatment options and among patients from populations with distinct genetic backgrounds.
For nearly a decade, there has been a lack of large-scale studies on the distribution and prognostic relevance of associated cytogenetic/molecular abnormalities in Chinese patients with ALL, although consensus has been reached on the poor prognosis of patients with t(9;22)(q34;q11)/BCR-ABL or t(11q23)/MLL rearrangements and the good prognosis of patients with ETV6 rearrangements. 2, 6 Hence, we screened the somatic genetics signatures of childhood and adult ALL in a total of 1091 Chinese patients and explored their prognostic significance.
The frequencies, clinical features and prognostic relevance of more than 17 cytogenetic/molecular markers were evaluated.
MATERIALS AND METHODS

Patient cohort and genetic abnormality analyses
Out of the 1452 cases diagnosed as primary ALL according to French --American --British classification 14 and treated in the Shanghai Institute of Hematology-based hospital network between November 1989 and December 2010 (Chen et al. 15 ), both the clinical and biological data were available to allow a detailed evaluation of prognostic impact of genetic markers in 1091 patients. Morphology, immunophenotypic and cytogenetic analyses were performed at the time of diagnosis. BCR-ABL, ETV6-RUNX1, TCF3-PBX1, MLL-MLLT1, MLL-AFF1 and SIL-TAL1, CALM-AF10 fusion genes, expression of HOX11, HOX11L2, CRLF2 and variant IKZF1, and NOTCH1 mutations were detected according to literatures 9,11,13,16 --22 as presented in the accompanying paper. All the data were re-reviewed by the Institutional evaluation group. This study was approved by the ethical board of the participating centers. All patients gave informed consent for both treatment and cryopreservation of bone marrow and peripheral blood according to the Declaration of Helsinki.
The treatment protocols of pediatric and adult ALL patients For 752 pediatric patients, three protocols were adopted over the long period of time from 1989 to 2010 (detailed protocols, see Gu et al. 23 and Liu et al.
24
). The conventional ALL-XH 99 protocol was used during 2000 --2005. 23 Briefly, this protocol included a VDLP regimen, followed by one cycle of cyclophosphamide associated with cytarabine (Ara-C) and 6-mercaptopurine. The consolidation therapy consisted of sequential use of high-dose methotrexate, VDLDex (vincristine, daunorubicin, L-asparaginase, dexamethasone) and EA regimens (etoposide, Ara-C). The above regimens for consolidation treatments should be applied for three cycles in patients with low risk and five cycles in patients with intermediate and high risk. The maintenance therapy consisted of 6-mercaptopurine and methotrexate for 3 weeks, followed by prednisone and vincristine in the last week, every month cyclically, combined with intermittent intensive chemotherapies using VDLDex, or EA regimen every year. Total therapy duration was 3 years for boys, 2 and a half years for girls in patients of low-risk group, 3 and a half years for all pediatric patients with high risk. In all, 206 patients entering into the study from November 1989 to December 1999 were treated with the Chinese ALL-88 protocol, in which no highdose Ara-C was given to the intermediate-risk and high-risk groups, but the COAP regimen (vincristine, cyclophosphamide, Ara-C, prednisone) was added. Since 2006, ALL-2005 protocol was given instead, 24 which was modified based on the ALL-XH-99 regimen. The most important change was to move the high-dose Ara-C from the consolidation treatment to the later maintenance in the intermediate-risk and high-risk groups, whereas conventional dosage (Ara-C 100 mg/m 2 /day, q12h, H, d1-7) was still used in the consolidation treatment as that was in low-risk group.
For adult patients, the induction regimens were VDP, VDCP or VDLCP, administered over a 4-week period, with more intensive chemotherapy in the recent years (V: vincristine 1.5 mg/m Because of the small number of patients (37 cases) who received allogenetic stem cell transplantation, they were not separated for further analysis.
Statistical analysis
Fisher exact P-test was used to compare the CR rate. The overall survival (OS) was defined as from the diagnosis of the disease to death or alive at last follow-up (censored); relapse-free survival (RFS) was measured from achieving CR to relapse, or any death and alive in CR (censored); and event-free survival (EFS) was from disease diagnosis to treatment failure such as relapse, refractory disease, death, or alive in CR at last follow-up (censored), which were estimated by Kaplan --Meier method and compared by log-rank test for stratifications of the risk groups. The last follow-up was carried out on August 2011. Two-side P-values less than 0.05 were considered statistically significant. Multivariate analyses of OS or RFS were performed using the Cox regression models. A limited backward selection procedure was used to exclude redundant variates. All statistical analyses were evaluated using SPSS 13.0 software (SPSS Inc., Chicago, IL, USA).
RESULTS
Characteristics of the patients
From November 1989 to December 2010, 1091 newly diagnosed ALL were enrolled for analysis, including 339 (31.07%) adults (X18 years, median 36 years) and 752 (68.93%) children (o18 years, median 6 years). Among 1020 cases with immunophenotypic data, the majority were B-ALL (869 cases), accounting for 85.20%, the T-ALL patients (140 cases) accounted for 13.73%, whereas only 11 cases corresponded to ALL of bi-immunophenotypes with either both B-and myeloid markers or T-and myeloid markers (1.08%). For the peripheral blood WBC, we established the cutoff points of 30 Â 10 9 /l and 100 Â 10 9 /l, respectively, as prognostic indicators of B-ALL and T-ALL, according to their known impact on prognosis. 25 The main characteristics of the patients are shown in Table 1 .
Comparison of prognosis of adults and children The CR rates in ALL of distinct immunophenotype groups and age groups are shown in Table 1 . By comparison of prognosis of adults (X18 years) and children (o18 years), we found that, both in B-ALL and in T-ALL, there were significant differences between patients' outcomes. In B-ALL (Figures 1a and b) , the median OS and RFS of adults were 16 months (95% CI 13.3 --18.7) and 9 months (95% CI 6.0 --12.0), respectively, whereas those of children had not yet been reached (both Po0.0001). In T-ALL, (Figures 1c and d) , the outcome of adults was still worse than that of children, with the median OS and RFS being 23 months (95% CI 12.7 --33.3) and 17 months (95% CI 3.7 --30.3), respectively, whereas those of children also had not been reached (P ¼ 0.005, P ¼ 0.039). Next, according to different age groups (patients younger than 1 year were not included in statistics because of too limited cases), more detailed observation of the OS and RFS (Figures 1e and f) revealed that the prognosis was inversely proportional to age (Po0.0001). The median OS and RFS of both 1 --9-year-old and 10 --14-year-old patients had not yet been reached, with the survival of the younger children being slightly better. The median OS and RFS of patients aged 15 --19 years were 26 months (95% CI 12.6 --39.4) and 21 months (95% CI 10.4 --31.6), and those of patients X20 years were 16 months (95% CI 13.1--18.9) and 9 months (95% CI 3.5 --14.5). It was also demonstrated that, with regard to either OS or RFS, the prognosis of the first two groups of patients (1 --9-year-old group and the 10 --14-year-old group) were similar, and those of the latter two groups (15 --19-year-old patients and patients X20 years) were close. Thus, the treatment outcome in the older group (age X15 years) was significantly poorer than that in the younger group (p14 years).
Outcome related to cytogenetic/molecular abnormalities According to the different characteristics of B-and T-ALL, we analyzed the outcomes of childhood and adult patients, respectively. We observed considerable impact of the cytogenetic/ molecular markers, such as hyperdiploidy (51 --65 chromosomes), Table 2 and Table 3 , respectively. To facilitate the comparisons with results of other groups, we quoted both median survival time and 5-year survival rates in childhood ALL. However, the prognosis of adult patients was relatively poorer, among which a few patients survived beyond 5 years, so we added the 3-year survival rates instead of the 5-year ones in the adult group. In the 607 childhood B-ALL patients, there were 128 (21.09%) relapses, 49 (8.07%) non-remitters and 129 (21.25%) deaths, including 67 (11.04%) with relapse. Analysis on the cytogenetic/ molecular markers mentioned above demonstrated very poor prognosis of the patients with t(9; 22)/BCR-ABL and Ik6 variant of IKZF1 gene. The median OS and RFS of the former patients were 31 and 17 months, respectively, and those of the latter were 43 and 21 months, respectively ( Table 2 ). As shown in Supplementary Table 1 , there was some overlap between the cases with t(9; 22)/BCR-ABL and those associated with Ik6 variant of IKZF1 gene, and the correlation was statistically significant (Po0.0001). Further dividing these two groups, we found that in the childhood B-ALL patients without Ik6 variant, the median OS and RFS of Ph ( þ ) cases were 32 months (95% CI 24.5 --39.5) and 21 months (95% CI 7.1 --34.9), respectively; whereas in Ph (À) childhood B-ALL patients, the median OS and RFS of Ik6 variant cases were 68 months (95% CI 23.5 --112.5) and 57 months (95% CI 17.1 --96.9), respectively.
In the 262 adult B-ALL patients, there were 107 (40.84%) relapses, 53 (20.23%) non-remitters, and 131 (50%) deaths, including 74 (28.24%) with relapse, all being much higher in adults as compared with those in children. Poor median OS, RFS and EFS were noted in the patients with t(9;22)/BCR-ABL, MLL-translocation, CRLF2-overexpression, Ik6 variant of IKZF1 gene, complex abnormalities (X3 chromosomes) and other structural changes. The overlapping situation of the aberrations was shown in Supplementary Table 2. For T-ALL, we analyzed the cytogenetic/molecular markers, such as del(1p)/SIL-TAL1, t(10;11)/CALM-AF10, HOX11 and HOX11L2 expression, and NOTCH1 mutations, and the results of childhood and adult cases were shown in Table 2 and Table 3 , respectively. The overlapping situation of the aberrations was shown in Supplementary Table 3 . In childhood T-ALL associated with del(1p)/SIL-TAL1, HOX11L2 expression or NOTCH1 mutations, the median OS were 23 months (95% CI 10.5 --35.5), 36 months (11.6 --60.4) and 23 months (5.4 --40.7), respectively. The median OS of patients with HOX11 expression had not yet been reached, indicating this marker as a favorable prognostic factor, whereas the patients with t(10;11)/CALM-AF10 were not included into the statistics because of limited case number (only 2 cases). In adult T-ALL associated with above-mentioned cytogenetic/molecular markers, poor median OS, RFS and EFS were noted, although the HOX11 expression showed an advantage over other groups as it did in childhood patients.
Ik6 variant of IKZF1 gene and CRLF2 overexpression predict a worse outcome in BCR-ABL-negative B-ALL patients We observed that the Ik6 variant of IKZF1 gene, CRLF2 overexpression and t(9;22)/BCR-ABL were closely related (co-existence) (Supplementary Table 1 ,2). Ik6 variant of IKZF1 gene (Po0.0001) and CRLF2 overexpression (P ¼ 0.107) were overlapped with t(9;22)/BCR-ABL. However, for all of the Ph-positive ALL patients, regardless of additional Ik6 variant of IKZF1 gene or overexpression of CRLF2, their prognosis was very poor. In the patients of Ph( þ ) with or without Ik6 or CRLF2 overexpression, the median OS was both 18 months (95% CI 8.1 --28.0 and 10.8 --26.2, respectively). Then, we compared, in the BCR-ABL-negative B-ALL patients, the prognosis of cases with IKZF1 gene wild type and that of those with Ik6 variant of IKZF1 gene. It was found that the median OS (Figure 2a ) of childhood patients of these two groups were not reached and 68 months (95% CI 23.4 --112.5), respectively, showing significant difference (P ¼ 0.001). In adult patients, the median RFS differed to some extent between the two groups (P ¼ 0.114) (Figure 2b ), being 14 months (95% CI 6.1 --21.9) in the former and 7 months (95% CI 4.1 --9.9) in the latter.
We also compared the prognosis of patients with different CRLF2 expression levels in BCR-ABL-negative B-ALL patients. It was found that the 5-year-OS of childhood patients with low CRLF2 expression were significantly better than those with high CRLF2 expression (77%, 95% CI 71 --83 vs 61%, 95% CI 43 --78), although the median OS both were not reached (Figure 2c , P ¼ 0.022). In adult patients, the same tendency existed in patients with low or high expression of CRLF2 as far as median RFS was concerned (17 months (95% CI 8.6 --25.4) vs 4 months (95% CI 1.7 --6.3), respectively, P ¼ 0.003), as shown in Figure 2d .
Based on these above data, we further compared the survival of these BCR-ABL-negative patients with BCR-ABL-positive B-ALL patients who had a worse prognosis (median OS of only 31 months, 95% CI 16.0 --46.0) in children (Figures 2e and f) . Of note, the prognosis of Ph-negative patients with Ik6 variant of IKZF1 gene was close to that of Ph-positive patients, whereas the outcomes of patients with high CRLF2 expression were better than the latter.
Cytogenetic/molecular risk groups in childhood B-ALL We classified 607 childhood B-ALL patients hierarchically into three cytogenetic risk groups (Figure 2i ). Patients with t(12;21)/ ETV6-RUNX1 and hyperdiploidy (51 --65) were recognized as lowrisk prognostic factors according to their good outcome. We also found in our analysis that the survival of childhood patients with t(1;19)/TCF3-PBX1 was similar to that of patients with these two cytogenetic/molecular abnormalities, even slightly superior to that of the hyperdiploidy group. (Figure 2g , P ¼ 0.221). Thus, we concluded the cytogenetic/molecular markers mentioned above to the low-risk group.
Patients with MLL translocations (including t(4;11)/MLL-AFF1, t(11;19)/MLL-MLLT1), t(9;22)/BCR-ABL and complex karyotype (X3 chromosomes) were assigned to the high-risk group. The median OS of patients with Ik6 variant of IKZF1 gene (excluding former three markers) was 68 months (95% CI 23.1 --112.9), and its OS curve was closely near the other three ones (Figure 2h , P ¼ 0.647), hence, they were also included into the high-risk group.
Patients with the rest of cytogenetic abnormalities and those without any cytogenetic abnormalities fell into the intermediaterisk group, including those with CRLF2 overexpression without coexistence of other high-risk cytogenetic abnormalities, such as the Ph and Ik6, and the median OS of these patients was not reached. By this classification, we observed (Figure 2j ) significantly different OS rates among these three groups (Po0.0001), with the median OS being not reached in the low-and intermediate-risk groups, and 43 months (95% CI 11.1 --74.9) in the high-risk group (the 5-year-OS of these three groups was 86% (95% CI 80 --92), 77% (95% CI 71 --83) and 48% (95% CI 37 --59), respectively). In addition, the RFS and EFS rates also showed obvious significances among these three groups (Figures 2k and l) .
On the contrary, the prognosis of adult ALL is generally quite poor, so we could not further stratify it by risks.
Results of multivariate analysis in B-ALL In B-ALL, multivariate analysis were conducted separately in childhood and adult groups, focusing on age, gender, WBC, In the total 1091 cases, the impact of the age was very significant (Po0.0001). When the age factor was re-analyzed separately in children and adults, it remained an independent prognostic factor of OS and RFS in children; whereas in the univariate analysis of OS in adults, there is a tendency of difference, especially between patients X50 years and o50 years (P ¼ 0.051), however, this difference was still removed in the multivariate analysis, probably due to the generally poor prognosis of adults.
It was noted that WBC count was a prognostic factor with significant impacts on the OS and RFS for both children and adults (Table 4) . It is noteworthy that, although the stages of treatment era didn't exert independent impact in multivariate analysis, they were related to OS and RFS in a statistically significant way among childhood B-ALL patients (Figure 1g ), but not adult (Figure 1h ), when studied in univariate analysis.
We also found that, for adult B-ALL, t(9;22)/BCR-ABL could independently predict OS and the independent prognostic factor for RFS was Ik6 variant of IKZF1 gene. For B-ALL in children, t(9;22)/ BCR-ABL, t(11q23)/MLL and Ik6 variant of IKZF1 gene all appeared as the independent factors for OS, but the independent adverse prognostic factors for RFS were only t(9;22)/BCR-ABL and Ik6 variant of IKZF1 gene. At the same time, we also observed that t(1;19)/TCF3-PBX1 and t(12;21)/ETV6-RUNX1 were both independent favorite factors for RFS in children (Table 4) .
DISCUSSION
Tremendous efforts have been made to identify prognostic factors in ALL to improve the treatment efficacy. 26 Clinical parameters such as age and WBC count are the first to be discovered, thus providing direct guidance to the treatment. 27, 28 However, these parameters are far from enough to explain the prognostic differences among patients, and the search for prognostic factors using sophisticated approaches has allowed genetic abnormalities to be defined as biomarkers, such as the t(9;22)/BCR-ABL predicting a very poor prognosis, and has resulted in different treatment strategies from other patients. 29, 30 After decades of endeavor, many important genetic molecular prognostic markers have been found, and patients can be divided into distinct groups according to the presence or absence of these markers.
Here, based on our own data in a large Chinese patient series, we divided the childhood B-ALL into three groups, that is, low-, intermediate-and high-risk groups, similar to the international classification. 2, 6 The t(12;21)/ETV6-RUNX1 and hyperdiploidy (51 --65) are known as low-risk factors, and a similar favorable prognostic impact of these markers was also shown in our patients. Interestingly, it was documented in our data that the survival of childhood patients with t(1;19)/TCF3-PBX1 was similar to that of patients with t(12;21)/ETV6-RUNX1 and hyperdiploidy (51 --65), which was supported by the experiences of St Jude Children's Research Hospital. 3 At the same time, in multivariate analysis, this marker was the independent favorite factor for RFS in children as well as t(12;21)/ETV6-RUNX1. Thereby, this group of patients was thus put into the low-risk group. In addition, we tried to evaluate the two recently reported molecular markers, namely CRLF2 overexpression and Ik6 variant of IKZF1 gene, by virtue of risk stratification. The relapse rate of patients in CRLF2-high-expression group was significantly higher than patients in the CRLF2-low-expression group, 20 but the former factor did not show its advantage in the multivariate analysis. 11 Ensor et al.
10
demonstrated in their study that CRLF2 deregulation (CRLF2-d) was associated with an inferior EFS and OS in the univariate analysis of their whole cohort, whereas not being an independent risk factor for EFS, RFS, or OS. Based on these multiple reasons, they believed that CRLF2-d should be classified into the intermediate cytogenetic risk group. IKZF1 status seemed to be even worse. Harvey et al. 11 reported that, in their multivariable analysis considering age, presentation leukocyte count, Hispanic/ Latino ethnicity, CRLF2 rearrangement, BCR-ABL1-like gene expression profile, IKZF1 alteration, JAK mutation and stepwise variable selection, only IKZF1 status remained significantly associated with risk of relapse at a P-value threshold of 0.05. Kuiper et al.
8 also reported in their study that the IKZF1 remained the strongest predictive factor for RFS and OS in the multivariate analysis.
In our study, we found the 5-year-OS of CRLF2 overexpression group without coexistence of other high-risk cytogenetic abnormalities was similar to the intermediate-risk patients, whereas that of the cases with Ik6 variant of IKZF1 gene was close to the average value of high-risk group. Indeed, as shown in Table 2 , only Ik6 variant of IKZF1 gene was an unfavorable prognostic marker in outcome analysis of childhood ALL, as the high-risk Ph was. In addition, in the multivariate analysis (Table 4) , only Ik6 variant of IKZF1 gene was the independent prognostic factor of both OS and RFS (P ¼ 0.001, P ¼ 0.032) as Ph was, whereas CRLF2 failed to be All of the factors with Po0.10 in the univariate analysis were subject to multivariate analysis afterwards, backward stepwise Cox proportional-hazard modeling was used in multivariate analysis of risk factors.
independent prognostic factors of both OS and RFS. It was based on these data that we put the CRLF2 overexpression cases to the intermediate-risk group, and cases with the Ik6 variant of IKZF1 gene into the high-risk group.
Results of our large-scale screening for molecular markers have shown that the distributions of molecular markers in 10 --14-year and 15 --19-year age groups were similar, although the latter group seemed to have more chromosomal structural changes and less numeric changes (Chen et al. 15 ). However, their outcomes differed from each other dramatically in prognostic analysis: the survival of 10 --14-year age group was closer to that of the 1 --9-year age group, with a median OS not been reached, whereas the survival of the 15 --19-year age group was closer to that of adults (X20 years), with a median OS of 26 months (95% CI 12.6 --39.4). How to interpret such a considerable difference in the outcome, despite of similar distribution of molecular markers? We believe that one of the important reasons may be the different treatment programs given to these two groups of patients. In China, the treatment programs used for 10 --14-year and 1 --9-year age groups were consistently pediatric therapy (see methods), and 15 --19-year age group mostly received adult treatment. As compared with the adult regimen, the treatment for children has always been more intense. Boissel et al. 31 reported that they had 77 and 100 adolescents (15 --20 years of age) enrolled in the pediatric FRALLE-93 and adult LALA-94 protocols, respectively, and found that, in terms of either OS or RFS, the use of regimens for children (FRALLE-93) favored the outcome when compared with the adult regimen (Po0.0001 and Po0.0001). Nachman et al. 32 randomized 262 patients (16 --21 years of age) into two groups and found that the treatment efficacy of augmentedtherapy group was significantly better than that of standardtherapy group. It can be concluded that, for ALL patients of the older children/younger adult group (15 --20 years), more intensive regimens have become a trend in the treatment and will gradually reach to an international consensus. Our results also confirmed the necessity of intensive chemotherapy for this group of patients. However, are there any other reasons in addition to the abovementioned ones? In this study, more chromosomal structural abnormalities were observed in 15 --19-year age group than in 10 --14-year age group. It is possible that the adolescent ones bear more unfavorable genetic risks.
In the mean time, we conducted with interest a parallel analysis on the correlation of treatment options with prognosis across the past 20 years. According to the evolution of treatment programs, we divided this long period into three intervals, namely, 1989 --1999, 2000 --2005 and 2006 --2010. Treatment options varied from the basic three-drug combination (VDP) to the multi-drug combination therapy (VDLCP) up to now, with a corresponding gradual improvement of the prognosis, especially in childhood B-ALL (Figures 1g and h) . However, why is the prognosis of adult ALL always much worse than that of children? Aside from the intensity of treatment programs, the significant differences among the distribution of abnormal molecular markers in adult and children may be another important reason. As a matter-of-fact, the unfavorable molecular markers, such as t(11q23)/MLL rearrangement, t(9;22)/BCR-ABL and Ik6 variant of IKZF1 gene dominated in adults. For these molecular markers predicting a very poor prognosis, we believe that it is not enough to increase the treatment intensity alone, and the key should be to adjust treatment strategies, for example, targeting molecules and/or networks involved in the pathogenesis of disease. In this regard, successful examples have already appeared in ALL, such as t(9;22)/ BCR-ABL. On one hand, BCR-ABL oncoprotein suggests a poor prognosis; on the other hand, molecular studies have proven that it is an ideal target for tyrosine kinase inhibitors. In recent years, exploration of the tyrosine kinase inhibitors (Imatinib, Dasatinib) in treatment of Ph-positive ALL cases has made encouraging progress, effectively reversing the poor prognosis it once predicted, 30, 33, 34 to the extent that this poor prognostic factor will be re-evaluated in the near future.
With the constant in-depth study on the pathogenesis of ALL and the continuous development and renewal of molecular detection techniques, a growing number of new molecular markers have been discovered, providing new therapeutic targets and directions at the same time. Along with the exploration and amendments on treatment strategies, the role of molecular markers in the prognosis predicting and the treatment is also evolving. Now that CRLF2 overexpression and Ik6 variant of IKZF1 gene are important indicators of prognosis of Ph-negative B-ALL patients, they may represent useful references in guiding novel therapies of ALL in the era of tyrosine kinase inhibitors, which will have reversed the fate of Ph-positive ALL patients in the near future.
